STENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends March 31
STERIS plc
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$221.97−0.69 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $21.73B
- P/E (TTM)
- 27.1
- Dividend yield
- 1.11%
STERIS plc revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare | $4.21B | $3.88B | $3.61B | $3.09B | – | – | – | – | – | – | 70.9% | +8.5% |
| Applied Sterilization Technologies | $1.14B | $1.04B | $954.00M | $914.43M | – | $685.91M | $627.15M | $555.13M | $513.29M | $477.84M | 19.2% | +9.6% |
| Life Sciences | $588.80M | $542.30M | $571.70M | $536.70M | – | $467.55M | $416.94M | $378.56M | $361.59M | $328.87M | 9.9% | +8.6% |
| Healthcare Specialty Services [Member] | – | – | – | – | – | – | $563.61M | $510.06M | $469.07M | $539.54M | – | – |
| Healthcare Products [Member] | – | – | – | – | – | – | $1.42B | $1.34B | $1.28B | $1.27B | – | – |
| OperatingSegmentAllExceptCorpandOther [Member] | – | – | – | – | – | $3.11B | $3.03B | $2.78B | $2.62B | $2.61B | – | – |
| Segment operating income | – | – | – | – | – | $3.11B | $3.03B | $2.78B | $2.62B | $2.61B | – | – |
| Healthcare | – | $3.88B | $3.61B | $3.09B | – | $1.95B | $1.99B | $1.85B | – | – | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Applied Sterilization Technologies | – | – | – | – | – | $310.65M | $270.92M | $221.83M | $196.30M | $176.40M | – |
| Life Sciences | – | – | – | – | – | $180.80M | $144.09M | $132.13M | $123.89M | $109.95M | – |
| Healthcare Specialty Services [Member] | – | – | – | – | – | – | $64.22M | $64.22M | $58.46M | $41.02M | – |
| Healthcare Products [Member] | – | – | – | – | – | – | $356.42M | $323.68M | $294.16M | $285.18M | – |
| OperatingSegmentAllExceptCorpandOther [Member] | – | – | – | – | – | $918.53M | $835.71M | $741.42M | $672.81M | $612.55M | – |
| Segment operating income | – | – | – | – | – | $699.38M | $628.70M | $556.52M | $509.81M | $475.14M | – |
| Corporate | – | – | – | – | – | -$219.15M | -$207.02M | -$184.90M | -$163.00M | -$137.40M | – |
| Healthcare | – | – | – | – | – | $427.09M | $420.71M | $387.47M | – | – | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $3.06B | $2.87B | $2.76B | $2.36B | $2.19B | $1.44B | $1.40B | $1.30B | $1.22B | $1.20B | 51.6% | +6.6% |
| Service [Member] | $2.88B | $2.59B | $2.37B | $2.17B | $2.03B | $1.66B | $1.63B | $1.49B | $1.40B | $1.41B | 48.4% | +11.1% |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.33B | $4.01B | $3.75B | $3.25B | $2.94B | $2.23B | $2.21B | $1.98B | $1.84B | $1.80B | 73.0% | +8.1% |
| Other foreign locations | $1.49B | $1.34B | $1.30B | $1.21B | $1.20B | $808.58M | $755.35M | $748.57M | $735.34M | $766.57M | 25.2% | +11.1% |
| Ireland | $108.50M | $107.30M | $82.70M | $74.29M | $81.86M | $71.91M | $63.82M | $56.78M | $48.25M | – | 1.8% | +1.1% |
| United Kingdom | – | – | – | – | – | – | – | $56.78M | $48.25M | $42.73M | – | – |
From the segment and revenue-disaggregation notes of Steris's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.